Clinical TrialChronic PainKetaminePlaceboCompleted

The Effectiveness of Continuous Ketamine Infusion (KONTINUE)

Prospective observational cohort (n=80) evaluating continuous intravenous ketamine infusion (0.5 mg/kg/day) plus magnesium sulfate (1000 mg/day) over 4 days for chronic pain.

Target Enrollment
80 participants
Study Type
Phase NA observational
Design
Non-randomized

Detailed Description

Prospective observational cohort (80 participants) assessing continuous IV ketamine 0.5 mg/kg/day combined with magnesium sulfate 1000 mg/day administered over four days in hospital for chronic pain.

Evaluations scheduled at day 15, 30 and 60 with outcomes focused on pain reduction and safety/tolerability assessments.

Study Protocol

Preparation

sessions

Dosing

4 sessions
5760 min each

Integration

sessions

Study Arms & Interventions

Ketamine infusion

experimental

Continuous IV ketamine 0.5 mg/kg/day for 4 days with magnesium sulfate 1000 mg/day in hospital

Interventions

  • Ketamine0.5 mg/kg
    via IV• continuous infusion• 4 doses total

    4-day continuous infusion, 0.5 mg/kg/day

  • Placebo
    via IV• daily• 4 doses total

    Magnesium sulfate 1000 mg/day IV (co-administered)

Participants

Ages
18 – 99
Sexes
Male & Female

Inclusion Criteria

  • Pain lasting for more than six months without contraindication to treatment

Exclusion Criteria

  • Inability to give consent
  • Severe psychiatric disorder

Study Details

  • Status
    Completed
  • Phase
    Phase NA
  • Type
    observational
  • Design
    Non-randomized
  • Target Enrollment80 participants
  • Timeline
    Start: 2022-02-22
    End: 2024-02-25
  • Compounds
    KetaminePlacebo
  • Topic
    Chronic Pain

Locations

Centre Hospitalier Princesse Grace — Monaco, Monaco

Your Library